癌症研究与免疫肿瘤学杂志
开放获取

抽象的

生酮饮食作为癌症的辅助治疗

塞皮德·阿明扎德·戈哈里

标题：生酮饮食作为癌症的辅助治疗

姓名：Sepideh Aminzadeh-Gohari ¹、 Daniela Weber ¹、 Luca Catalano ¹、 Silvia Vidali ¹、 David Licha ²、 Julia Tevini ³、 René Günther Feichtinger ¹、 Peter Kölblinger ⁴、 Johannes Adalbert Mayr ⁵、 Wolfgang Sperl ⁵、 Michael Emberger ⁶、托马斯·菲尔德³、克里斯蒂安·胡贝尔²、罗兰·朗⁴、芭芭拉·科夫勒¹

 

¹受体生物化学和肿瘤代谢研究项目，帕拉塞尔苏斯医科大学，萨尔茨堡，奥地利

²萨尔茨堡大学生物分析研究实验室，奥地利萨尔茨堡。

³奥地利萨尔茨堡帕拉塞尔苏斯医科大学检验医学系。

⁴帕拉塞尔苏斯医科大学皮肤科，奥地利萨尔茨堡

⁵帕拉塞尔苏斯医科大学儿科，奥地利萨尔茨堡

⁶ Patholab，奥地利萨尔茨堡

 

抽象的
Most solid cancer cells are characterized by the Warburg effect, a biochemical phenomenon in which cancer cells predominantly utilize glycolysis instead of oxidative phosphorylation (OXPHOS) for producing energy and building blocks for maintaining continuous cell proliferation. Due to the high glucose dependency of tumor cells combined with a decreased capacity to utilize alternative substrates via OXPHOS, certain dietary interventions such as the ketogenic diet (KD) - a high fat/low carbohydrate diet could sensitize them to classical cancer therapies. Owing to the KD’s low carbohydrate content, the KD provokes the reduction of circulating glucose, consequently lowering insulin and IGF-1 levels. Insulin and IGF-1 receptor signaling pathways are significantly involved in tumorigenesis. Our present as well as previous mouse studies show that the KD successfully target different types of cancer such as neuroblastoma (NB), breast cancer (BC) and melanoma (MEL). However, the KD could be deleterious in the treatment of certain types of cancer with cancer-related anorexia/cachexia syndrome and/or paraneoplastic syndrome, as we observed with renal cell carcinoma. Our molecular investigations suggest that the KD targets cancer cells through various mechanisms such as reducing angiogenesis, inducing energy stress, altering the lipid and metabolite signature systematically and in the tumor tissue. Our studies indicate that the KD could be considered as part of multimodal therapy for NB, BC and MEL.

演讲者简介：

Sepideh Aminzadeh-Gohari 在伊朗完成了细胞与分子生物学学士和硕士学位，随后在该行业工作了 4 年。为了继续学业，她于 2013 年移居奥地利，并于 2019 年在帕拉塞尔苏斯医科大学附属医院 Barbara Kofler 教授实验室获得博士学位，研究方向为“生酮饮食作为癌症辅助疗法，主要针对神经母细胞瘤”在萨尔茨堡。她发表了 15 篇论文，并获得了一项关于黑色素瘤体外代谢靶向的年轻研究资助。目前，她是受体生物化学和肿瘤代谢研究项目的博士后。

摘要引用：

世界癌症与诊断大会

德国法兰克福 - 2020 年 6 月 15 日至 16 日